VAY736 lower dose + VAY736 higher dose
Phase 1/2Withdrawn 0 views this week 0 watching💤 Quiet
Interest: 24/100
24
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Sjögren's Syndrome
Conditions
Primary Sjögren's Syndrome
Trial Timeline
Dec 1, 2015 → Sep 1, 2017
NCT ID
NCT02495129About VAY736 lower dose + VAY736 higher dose
VAY736 lower dose + VAY736 higher dose is a phase 1/2 stage product being developed by Novartis for Primary Sjögren's Syndrome. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT02495129. Target conditions include Primary Sjögren's Syndrome.
What happened to similar drugs?
20 of 20 similar drugs in Primary Sjögren's Syndrome were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
9
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02495129 | Phase 1/2 | Withdrawn |
Competing Products
20 competing products in Primary Sjögren's Syndrome